NAVB - Navidea Biopharm GAAP EPS of -$0.12 revenue of $0.05M March, 23 2022 07:39 AM Navidea Biopharmaceuticals Inc. Navidea Biopharm press release (NYSE:NAVB): Q4 GAAP EPS of -$0.12. Revenue of $0.05M (-77.3% Y/Y). cash and cash equivalents of $4.2M For further details see: Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M